Production Unit
Our Finished Dosage Form - EU Portfolio consists of the following products:
| S.No. |
Product Name |
Strength |
Pack Size |
|
Liquid Injectables
|
|
|
|
| 1. |
Busulfan Injection
|
6 mg/mL
|
60 mg/10 mL
|
| 2. |
Carboplatin Injection
|
10 mg/mL |
50 mg/5 mL
|
150 mg/15 mL
|
450 mg/45 mL
|
600 mg/60mL
|
| 3. |
Cytarabine Injection
|
100 mg/mL
|
100 mg/1 mL
|
500 mg/5 mL
|
1g/10 mL
|
2g/20 mL
|
| 4. |
Docetaxel Injection
|
20 mg/mL
|
20 mg/1 mL
|
80 mg/4 mL
|
120 mg/6 mL
|
160 mg/8 mL
|
180 mg/9 mL
|
| 5. |
Etoposide Injection
|
20 mg/mL
|
100 mg/5 mL
|
200 mg/10 mL
|
500 mg/25 mL
|
1g/50 mL
|
| 6. |
Gemcitabine Injection (RTU)
|
38 mg/mL
|
200 mg/5.26 mL
|
1g/26.3 mL
|
2g/52.6 mL
|
| 7. |
Irinotecan Hydrochloride Injection (Terminal Sterilization)
|
20 mg/mL
|
40 mg/2 mL
|
100 mg/5 mL
|
300 mg/15 mL
|
500 mg/25 mL
|
| 8. |
Oxaliplatin Injection
|
5 mg/mL
|
50 mg/10 mL
|
100 mg/20 mL
|
200 mg/40 mL
|
| 9. |
Paclitaxel Injection
|
6 mg/mL
|
30 mg/5 mL
|
100 mg/16.7 mL
|
150 mg/25 mL
|
300 mg/50 mL
|
| 10. |
Pemetrexed Injection
|
25 mg/mL
|
100 mg/4 mL
|
500 mg/20 mL
|
1000mg/40ml
|
| 11. |
Cabazitaxel Injection
|
20 mg/mL
|
60mg/3mL
|
| 12. |
Bendamustine Hydrochloride for Injection
|
25 mg/vial
|
25 mg/vial |
| 100 mg/vial |
100 mg/vial
|
|
|
|
| 13. |
Gemcitabine for Injection
|
200 mg/vial
|
200 mg/vial
|
1g/vial
|
1g/vial
|
2g/vial
|
2g/vial
|
| 14. |
Pemetrexed for Injection
|
100 mg/vial
|
100 mg/vial
|
500 mg/vial
|
500 mg/vial
|
| 15. |
Bortezomib For Injection
|
3.5 mg/vial
|
3.5 mg/vial
|
1.0 mg/vial
|
1.0 mg/vial
|
2.5 mg/vial
|
2.5 mg/vial
|
| 16. |
Azacitidine for Injection
|
100 mg/vial
|
100 mg/vial
|
| 17. |
Thiotepa for Injection
|
15 mg/vial
|
15 mg/vial
|
| 100 mg/vial |
100 mg/vial
|
| 18. |
Lacosamide Injection
|
10 mg/vial
|
200 mg/20mL
|
| 19. |
Vancomycin for Injection
|
1mg/vial
|
1mg/vial
|
500mg/vial
|
500mg/vial
|
| 20. |
Caspofungin for Injection
|
50 mg/vial
|
50 mg/vial
|
70 mg/vial
|
70 mg/vial
|
Fresenius Kabi Oncology Ltd. do not intend to manufacture any product commercially until there is a valid IP. Listing of product shall not be construed in any way that Fresenius Kabi Oncology has violated any IP laws of the land.
